PanGen Biotech Inc. (222110.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩4,490 (-1.97%) as of
Key statistics
- Market cap
- 60.68B
- Dividend yield
- 0.00%
- 52-week range
- 4,220.00 – 8,510.00
- Beta
- -0.12
- Revenue (TTM)
- 14.18B
- Profit margin
- 7.99%
- Volume
- 3.89k
About PanGen Biotech Inc.
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suwon-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.